STOCK TITAN

Editas Medicine to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:

  • Wells Fargo 2021 Virtual Healthcare Conference
    Fireside Chat (Virtual)
    Date: Friday, September 10, 2021
    Time: 8:00 a.m. ET
  • Morgan Stanley 19th Annual Global Healthcare Conference
    Fireside Chat (Virtual)
    Date: Tuesday, September 14, 2021
    Time: 9:30 a.m. ET

The events will be webcast live and can be accessed on the Editas Medicine website in the Investors section. Archived recordings will be available for approximately 30 days following the events.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investors
Ron Moldaver
(617) 401-9052
ir@editasmed.com


Editas Medicine, Inc.

NASDAQ:EDIT

EDIT Rankings

EDIT Latest News

EDIT Stock Data

428.44M
75.99M
0.91%
80.47%
20%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About EDIT

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.